A Coding Region instability Determinant-Binding Protein (CRD-BP) binds in vitro to c-myc mRNA and appears to stabilize the mRNA. The CRD-BP gene is ampli®ed in one-third of human breast cancer cases, and the CRD-BP appears to be an oncofetal protein. To analyse CRD-BP expression in human cancer tissue, paired extracts of cancer and normal colon specimens from 21 patients were analysed by immunoblotting and/ or reverse transcriptase-polymerase chain reaction. Seventeen cancer specimens out of 21 (81%) were positive for CRD-BP expression by one or both assays. With one exception, normal colon specimens were negative for CRD-BP expression; specimens of in¯am-matory bowel and a villous adenoma also had no detectable CRD-BP. The lack of CRD-BP expression in normal colon did not result from indiscriminate protein or RNA degradation. c-myc mRNA levels appeared to be elevated in tumor specimens. We conclude that the CRD-BP is scarce or absent from normal colon but is overexpressed in colorectal cancer. The CRD-BP might be a novel human tumor marker. Oncogene (2001) 20, 6544 ± 6550.
Introduction
Mutations in RNA-binding protein genes occur in several human diseases including familial mental retardation (Nussbaum and Ledbetter, 1995) . We are investigating an mRNA-binding protein with potential links to human cancer. This protein binds with high speci®city to a *250 nucleotide segment of the c-myc mRNA coding region. This RNA segment causes cmyc mRNA to be unstable in cells and is designated the Coding Region instability Determinant or CRD (Bernstein et al., 1992; Herrick and Ross, 1994) . The protein of interest, the CRD-Binding Protein (CRD-BP), contains 577 amino acids and includes multiple RNA-binding motifs: two ribonucleoprotein (RNP) domains, one arginine-glycine-glycine (RGG) RNAbinding domain, and four hnRNP K-homology (KH) domains (Doyle et al., 1998; Prokipcak et al., 1994) . The CRD-BP is orthologous to proteins that bind to other mRNAs Nielsen et al., 1999) and is related to a human protein overexpressed in pancreatic cancer (Mueller-Pillasch et al., 1997) , a human hepatocellular carcinoma autoantigen (Zhang et al., 1999) , and several developmentally regulated Xenopus proteins (Pfa and Taylor, 1992; Deschler et al., 1998; Havin et al., 1998) . Cell-free mRNA decay experiments indicate that the CRD-BP, when bound to c-myc mRNA, shields the mRNA from ribonuclease attack (Bernstein et al., 1992; Prokipcak et al., 1994; Doyle et al., 1998) . Therefore, the CRD-BP might prolong the half-life of c-myc mRNA in cells and can thereby increase the abundance of c-myc mRNA and cMyc protein. Since c-Myc protein is growth-enhancing, CRD-BP expression might correlate with increased cell replication.
Two properties of the CRD-BP link it to human cancer. (i) It is expressed abundantly in transformed (neoplastic) human tissue culture cell lines and in fetal rodent tissues but is undetectable in adult rodent tissues (Leeds et al., 1997; see also Nielsen et al., 1999 Nielsen et al., , 2001 Mueller-Pillasch et al., 1999) . Therefore, the CRD-BP has the properties of an oncofetal protein.
(ii) The CRD-BP gene is ampli®ed in approximately onethird of human breast cancer cases (Doyle et al., 2000) . In view of these ®ndings, we have begun to ask if the CRD-BP itself is overexpressed in human carcinomas. Preliminary immunoblotting (Western) assays indicated strong CRD-BP expression in some colorectal cancer specimens. Therefore, we focused on colon cancer and report here that the CRD-BP is overexpressed in 17 of 21 human colon cancer patients but not in normal colon or in in¯ammatory bowel tissue.
Results
Fresh frozen tissue specimens were obtained at surgery from colorectal cancer patients. Each patient provided two specimens: one from the cancer and a second from normal colon. Cytoplasmic extracts from 16 randomly selected tissue pairs (normal and cancer) were initially tested for CRD-BP expression by immunoblotting. A typical experiment with specimens from four patients is shown in Figure 1 . A distinct CRD-BP band that migrates at the same position as authentic CRD-BP was observed in two cancer specimens (patients 13 and 14; large arrow; lanes marked`C'). In most of the tumor specimens we have analysed, a prominent lower molecular weight immunoreactive band was also observed (Figure 1 , thin arrow). This smaller band was detected even in tumor specimens lacking a clearly visible CRD-BP-sized band (Figure 1 , patients 7 and 8). We have not further investigated this smaller band but suggest it might be a CRD-BP degradation product. If so, then the CRD-BP would be expressed in all four of these patients' cancer specimens (and in others as well). The RT ± PCR data described below con®rm that the CRD-BP is expressed in most colon cancer patients.
No CRD-BP was detected in normal colon from the four patients analysed in Figure 1 (lanes marked`N' ). Moreover, of the 16 normal specimens analysed by immunoblotting, all but one (patient #12) were negative for CRD-BP expression (Table 1 and data not shown). To determine if the lack of CRD-BP expression in normal colon resulted from indiscriminate protein degradation, each extract analysed in Figure 1 was electrophoresed in an SDS gel, and the gel was stained with Coomassie blue. The bands in the normal (N) and cancer (C) lanes were similar or identical, and there was no evidence of extensive protein degradation (Figure 2) . Therefore, the absence of detectable CRD-BP in normal colon did not result from extensive protein degradation in these specimens.
To con®rm the immunoblotting data using an independent and more sensitive technique, cytoplasmic RNA was analysed by RT ± PCR in a three-step experiment. In step one, single-stranded cDNA was generated by random priming of colon RNA with DNA hexamers. In step two, the cDNA was ampli®ed with primers for GAPDH mRNA, a housekeeping product which should be expressed in all cells. If a GAPDH signal was observed for both tumor and normal specimens from a patient, we assumed the samples were suitable for step three, which was PCR with CRD-BP-speci®c primers. If no GAPDH signal was observed, the specimen was considered to contain highly degraded RNA and was not further analysed. RNA extracts from 20 specimen pairs generated a GAPDH cDNA product and were further analysed for CRD-BP expression. Two ulcerative colitis specimens, one in¯ammatory bowel specimen, and a villous adenoma specimen also generated GAPDH DNA and were analysed for CRD-BP.
A typical RT ± PCR experiment with specimens from three patients is shown in Figure 3 . The normal and cancer specimens from each patient generated a GAPDH band (lanes 1, 2, 5, 6, 9, 10). However, only the cancer specimens generated a CRD-BP band (lanes 3, 7, 11; denoted by C). None of the normal specimens contained detectable CRD-BP (lanes 4, 8, 12; denoted by N). A CRD-BP band was not generated in control reactions in which water was substituted for RNA (lanes 17 and 18; denoted by W). Therefore, the CRD-BP DNA product is speci®c for colorectal cancer.
Of the 20 GAPDH-positive pairs of RNA samples, 16 cancer specimens (80%) generated a CRD-BP band ( . These four controls reinforce the notion that CRD-BP expression is restricted to colorectal cancer tissue. The one normal positive specimen (from patient #12) could be an exception. However, it seems more likely that there was an error in specimen collection or a lab mistake with patient #12, because even a very sensitive technique such as RT ± PCR failed to detect CRD-BP expression in any other normal specimen. c-myc expression in patient #12 was also aberrant (Figure 6 ), consistent with an error in specimen identi®cation. Additional samples of this patient's tissues were unavailable for further testing.
Failure to detect any CRD-BP mRNA in normal specimens by RT ± PCR was not the result of indiscriminate RNA degradation. Two experiments support this conclusion. First, each of the 20 RNA samples analysed for CRD-BP expression generated a GAPDH RT ± PCR product ( Figure 3 and data not shown). Therefore, the mRNA in these specimens was not fully degraded. Second, all GAPDH-positive RNA samples were electrophoresed in an agarose gel, and the RNA was visualized by ethidium bromide staining. None of these RNAs was completely degraded ( Figure  5 ). In most samples, prominent 28S and 18S rRNA bands were observed, indicating that the RNAs were intact or semi-intact. A minority of the specimens did contain partially degraded RNA. This result was not unexpected, since there is unavoidable variability between the time of tissue harvesting and freezing during surgery. However, RNA from normal specimens was not more degraded than RNA from cancer specimens. Table 1 . R: recombinant CRD-BP used as a positive control. N: normal colon tissue. C: colon cancer tissue. Large arrow: full-length CRD-BP. Thin arrow: immunoreactive band that migrates faster than full-length CRD-BP In summary, these RT ± PCR data con®rm and extend the major conclusion from the immunoblotting data, viz., the CRD-BP is expressed in 17 of 21 colorectal cancer tissues (81%) but is not detected in normal colon, in a villous adenoma, or in in¯amma-tory bowel tissue (Table 1) . The RT ± PCR reactions were non-quantitative. Therefore, we cannot judge whether CRD-BP abundance varies signi®cantly among the various tumor specimens.
Having observed CRD-BP expression in colorectal cancer but not in normal colon, we then assessed c-myc mRNA expression in the 20 GAPDH-positive patient specimens. c-myc mRNA and/or protein are known to be elevated in 66 to 80% of colorectal cancers, relative to normal colon (Sikora et al., 1987; Finley et al., 1989; Imaseki et al., 1989; Smith et al., 1993) . Our data con®rm these ®ndings ( Figure 6 ). A c-myc RT ± PCR product was observed in 17 of the 20 cancer specimens and in 6 of the 20 normals. (A faint band was present in the cancer and normal lanes of patient 15.) c-myc was also detected in three of the four tumor specimens that do not generate a CRD-BP band ( Figure 6 , patients 2, 3, 4 and 11). The c-myc RT ± PCR assays were not quantitative, and the percentage of tumor cells in each cancer specimen is unknown. Therefore, these data do not address the extent to which c-myc mRNA is overexpressed in colon cancers or whether cmyc expression is higher in CRD-BP-expressing tumors than in CRD-BP-de®cient tumors. Additional studies exploiting laser capture microdissection technology and quantitative RT ± PCR are necessary to address these issues.
It is also unclear at this point whether CRD-BP expression correlates with disease stage or with metastasic disease (Table 1 ). The tumors we analysed were adenocarcinomas, most of which were moderately dierentiated. Some CRD-BP-positive tumors had not metastasized, while two CRD-BP-negative tumors had metastasized to lymph nodes (Table 1 , patients 2 and 
Discussion
These data indicate that the CRD-BP is speci®cally expressed in colorectal cancers. With one exception, which appears to be artefactual, the CRD-BP is undetectable in normal colon, in¯ammatory bowel tissue, and one adenoma. We do not understand the molecular basis for tumor-speci®c CRD-BP induction but oer two possible explanations. One is that excess c-Myc protein in colorectal cancers activates CRD-BP gene transcription. Consistent with this idea, the CRD-BP promoter contains a strong c-Myc consensus binding site (P Farnham, personal communication) . On the other hand, at least some normal colon specimens contain c-Myc, so it is unclear why normal colon cells fail to accumulate at least low levels of CRD-BP. A second possibility is that CRD-BP induction is linked to inactivation of the APC gene. APC encodes a tumor suppressor that is mutated in familial adenomatous polyposis and is inactivated in most cases of spontaneous colorectal cancer (Kinzler and Vogelstein, 1996) . APC inactivation results in the up-regulation of b-catenin. While there is no obvious b-catenin binding site in the CRD-BP promoter, it is tempting to speculate that excess b-catenin activates CRD-BP gene transcription, directly or indirectly, in colorectal cancers.
Additional studies are required to address these possibilities and to determine if the CRD-BP is expressed in other carcinomas. Preliminary evidence indicates it is expressed in breast cancer but not in normal breast tissue (BB and JR, unpublished observations). If it is expressed in carcinomas but not in normal tissues, then the CRD-BP could be a highly speci®c human tumor marker having little or nò background' expression in normal cells. Additional questions need to be addressed: Can CRD-BP expression be monitored in tissue sections, for example by immunohistochemistry, to serve as an aid in identifying small numbers of neoplastic cells? Is the CRD-BP present only within tumor cells, or can it escape from cells and enter the circulation? Do patients make antibodies against it? Can the CRD-BP or its mRNA be detected in circulating colorectal tumor cells or in cells from stool specimens (Alexander and Raicht, 1998; Castells et al., 1998) ? These questions further highlight the importance of the lack of detectable CRD-BP in normal colon and other normal tissues (Leeds et al., 1997; Figures 1, 3, 4) . Using a tumor marker whose expression is undetectable in normal tissue would alleviate certain diagnostic dilemmas Figure 3 RT ± PCR detection of CRD-BP and GAPDH mRNA expression in colon specimens from three patients. RT ± PCR was performed as per Materials and methods using GAPDH primers and primer set A for CRD-BP. Lanes 1 ± 12: colon cancer (C) and normal colon (N) samples from three patients. Four lanes are shown for each patient, two cancer specimens and two normal specimens. Patient numbers are indicated below the line for each pair of normal and cancer specimens. Patients are listed in Table 1 . Lanes 13 ± 18: controls. H: RNA from HeLa cells, which serves as a positive control for CRD-BP expression. W: Water was used in the cDNA synthesis step in place of RNA. This reaction serves as a negative control and ensures that the PCR reagents are not contaminated. Lanes 1, 2, 5, 6, 9, 10 and 13 ± 15: GAPDH primers. The GAPDH band is noted on the left. Lanes 3, 4, 7, 8, 11, 12 and 16 ± 18: CRD-BP primers. The CRD-BP band is noted on the left Table 1 . Top panel: CRD-BP primer set A was used for PCR. Middle panel: CRD-BP primer set A was used for PCR. The last four lanes are specimens of ulcerative colitis tissue (U), in¯ammatory bowel tissue from patient #17 (I), and a villous adenoma (A). Bottom panel: CRD-BP primer set B was used, because primer set A did not generate a PCR product with these samples encountered with other tumor markers. For example, carcinoembryonic antigen (CEA) and prostate-speci®c antigen (PSA) are expressed in normal cells as well as in tumor cells of the intestine and prostate, respectively (Compton et al., 2000; Scher et al., 2000) . Circulating CEA and PSA levels can increase as a result of cancer, benign hypertrophy, and/or in¯ammation. Therefore, the basis for an elevated CEA or PSA reading can be dicult to discern. A CRD-BP test would reduce or eliminate this ambiguity by virtue of a low signal to noise ratio, since CRD-BP expression is low or nil in normal and in¯amed colon.
Two observations suggest the CRD-BP might also be a therapeutic target for colorectal cancer. First, its expression is restricted primarily or exclusively to colon cancer cells. It is not detected in normal colon. Second, inhibiting its function could speci®cally block cancer cell replication, for the following reason. The CRD-BP appears to stabilize c-myc mRNA (Bernstein et al., 1992; Herrick and Ross, 1994; Prokipcak et al., 1994; Doyle et al., 1998) . Therefore, we predict that CRD-BP expression would increase the abundance of c-myc mRNA and protein in carcinoma cells. Since c-Myc protein enhances cell replication (Spencer and Groudine, 1991) , tumor cells expressing the CRD-BP might have a growth advantage over their non-neoplastic counterparts. By blocking CRD-BP function in tumor cells, c-myc mRNA would be destabilized. The levels of c-myc mRNA and protein would fall, the growth advantage would be nulli®ed, and tumor cell replication might slow or stop. Normal cells lack the CRD-BP and would be unaected by CRD-BP inhibitors.
Materials and methods

Tissue specimens
Frozen surgical specimens were obtained from the Cooperative Human Tissue Network (CHTN), Columbus, OH, USA. Two specimens were obtained from each colorectal cancer patient. One was from the cancer itself or from a metastasis; the other was from normal colon/rectum removed at the time of surgery. Pathological diagnoses for each tissue specimen were provided by the CHTN. Ulcerative colitis, in¯ammatory bowel, and adenoma tissue were also obtained from the CHTN.
Immunoblotting
Cytoplasmic protein extracts were prepared as previously described (Leeds et al., 1997) . Eighty mg of protein were electrophoresed in a 7% SDS polyacrylamide gel and transferred to a nitrocellulose membrane (Protran TM , BA85; Schleicher & Schuell). Subsequent steps were performed as described (Leeds et al., 1997) , but the membrane was probed with rabbit anti-human CRD-BP peptide antibody and then with HRP-conjugated secondary antibody. The CRD-BP Figure 5 Electrophoresis of patient RNA samples in agarose gels. Cytoplasmic RNA samples from the indicated patients were electrophoresed for 15 min at 80 volts in a 1% agarose mini-gel. RNA bands were visualized and photographed using ultraviolet light. The prominent upper and lower bands are 28S and 18S ribosomal RNAs, respectively antibody was made by injecting a CRD-BP peptide (SVTGAAPYSSFMQAP) into rabbits. This sequence is located between the second and third KH domains of the CRD-BP (Doyle et al., 2000) . Immunoreactive CRD-BP was visualized by enhanced chemiluminescence.
Reverse transcriptase-polymerase chain reaction (RT ± PCR)
RNA was extracted from a portion of each tissue specimen using an RNAwiz TM kit (Ambion). First strand cDNA was generated by random priming with DNA hexamers (Boehringer-Mannheim). Then, double-stranded cDNA was synthesized in a 40-cycle reaction from approximately 1 mg of RNA using primers for glyceraldehyde phosphate dehydrogenase (GAPDH) mRNA (5'-ACCACAGTCCATGCCATC-3' and 5'-GTCCACCACCCTGTTGCTGTA-3'). If a GAPDH signal was observed with the tumor and normal samples from a patient, we assumed these samples contained RNA that was suciently intact for RT ± PCR. Therefore, GAPDH-positive samples were assayed for CRD-BP mRNA. Two primer sets were used for CRD-BP DNA ampli®cation. Primer set A (5'-CCACCCCTGAGGGCTGCTCC-3' and 5'-ACCTTCTTCA-GGTTCCGTCC-3') was used ®rst. Primer set A spans intron #14 of the CRD-BP gene (Doyle et al., 2000) . Therefore, PCR products of the appropriate size (163 ± 167 base pairs) had to be generated from CRD-BP mRNA, not the CRD-BP gene or CRD-BP pre-mRNA. If no signal was observed with primer set A, we used primer set B (5'-CCAGACCCCT-GATGAGAACG-3' and 5'-CCGTTGTTGTCCTGGACT-CG-3'), which spans intron #7 (Doyle et al., 2000) . Primers for c-myc mRNA were 5'-GGGGAATTCTGCTCCATGAG-GAGACA-3' and 5'-GGGAGATCTGCCCAAAGTCCAAT-TTG-3'. PCR products were electrophoresed in an agarose gel and visualized by ethidium bromide staining.
Electrophoresis of RNA
Cytoplasmic RNA extracts were electrophoresed for 15 min in an ethidium bromide-containing 1% agarose mini-gel. The gels were then photographed directly under UV light.
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